Journal of Hematology & Oncology 2025

4 papers
The 2025 edition of the Journal of Hematology & Oncology emphasizes the intersection of molecular biology and global health epidemiology. Research focuses on the tumor microenvironment, specifically the modulation of epithelial-mesenchymal transition to enhance targeted therapies. Notable work includes the identification of the GRN gene as a regulator bridging chemotherapy and immunotherapy responses in small cell lung cancer. Additionally, the journal features advancements in cellular engineering, such as the development of pluripotent stem cell-derived CAR-NK cells designed to treat T-cell malignancies while avoiding fratricide. Beyond molecular studies, the year's publications address the global burden of disease, analyzing trends in breast, cervical, ovarian, and uterine cancers from 1990 to 2021. These studies utilize disability-adjusted life years and age-standardization to quantify health loss and the transition toward lifestyle-driven chronic diseases. Methodological research also explores hub gene identification in biological networks and the inference of immune infiltration from bulk transcriptomic data. Prolific contributors include Alan Prem Kumar, Anjali P. Kusumbe, and Antonino Glaviano, reflecting a multidisciplinary approach to oncology and hematology.

Top Research Directions

The 6 research directions with Journal of Hematology & Oncology 2025 papers, ranked by paper count. Share is the fraction of the edition’s papers in the direction.

#DirectionPapersShare
1Demographic Normalization in Epidemiological Analysis125.0%
2How Diagnostic Disparities Distort Global Epidemiological Models125.0%
3Log-Linear Trend Analysis for Longitudinal Health Metrics125.0%
4Quantifying Disease Burden Attributable to Modifiable Risk Factors125.0%
5Quantifying the Total Burden of Disease125.0%
6The Global Shift Toward Chronic Disease Burden125.0%

Download all directions as CSV

Institutions

Institutions credited by Journal of Hematology & Oncology 2025 papers: a paper credits every institution named in its affiliations, once. 2 institutions share 2 credited papers.

#InstitutionPapersShare20242024 rank
1Icahn School of Medicine at Mount Sinai 150.0%0—
2Zhejiang University 150.0%0—

Download all institutions as CSV

About this data

Papers. Journal of Hematology & Oncology 2025 lists 4 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 2 of 4 papers (50.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-17 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Hematology & Oncology 2025”, https://lacuna.tiptreesystems.com/venue/journal-of-hematology-oncology/2025.

Papers

Title
Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies
Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Transcriptional regulatory network analysis identifies GRN as a key regulator bridging chemotherapy and immunotherapy response in small cell lung cancer